AMCP CEO Discusses Adherence, Out-of-Pocket Costs, and Concerns over the Inflation Reduction Act
In the third part of this video series, Susan Cantrell, CEO of AMCP, discusses the impact of drug prices on patient adherence with Managed Healthcare Executive.
In the third part of this video series, Susan Cantrell, CEO of AMCP, discusses the impact of drug prices on patient adherence.
While cost-sharing can be expressed as a well-intended benefit design, studies show it can negatively affect long-term adherence, Cantrell shared. AMCP supports efforts to reduce out-of-pocket costs, however when it comes to premiums and long-term consequences, there could be consequences.
She also highlighted the Inflation Reduction Act (IRA), expressing concerns about potential unintended consequences, such as manufacturers adjusting launch prices.
AMCP historically opposes government intervention in pricing, as it’s important to monitor any cost-shifting changes. Cantrell added AMCP actively works with others, sharing thoughts and helpful materials about how policies are put into action.
Jack Linehan of Epstein Becker Green Discusses Drug Coupons, Accumulators
July 9th 2020In this week's episode of Tuning Into The C-Suite podcast, Senior Editor Peter Wehrwein has a conversation with John "Jack" Linehan, a lawyer for Epstein Becker Green, about coupons and accumulators. Jack is an expert on drug distribution and reimbursement, and few people know as much about coupons and accumulators as he does. Peter and Jack go over some of the basics, who is advantaged and disadvantaged, and then dive into some the details on CMS regulations and how recent proposed changes to Medicaid best price rules would, if finalized, affect coupons and accumulators.
Listen
